Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)

NCT05096390 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT05096390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05096390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2022
Completion date
June 30, 2026
Enrollment
72 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

papillary renal cell carcinoma type 2